Literature DB >> 12041675

Failure to detect Epstein-Barr virus (EBV) DNA in plasma by real-time PCR in a case of EBV-associated posttransplantation lymphoproliferative disorder confined to the central nervous system.

Teruhiko Terasawa1, Haruhiko Ohashi, Keitaro Tsushita, Makoto Utsumi, Eiichiro Mukai, Shigeo Nakamura, Masanori Shimoyama.   

Abstract

We report here a patient who developed multiple central nervous system (CNS) space-occupying lesions 6 months after bone marrow transplantation from an HLA-matched unrelated donor. He had extensive chronic graft-versus-host disease and severe thrombocytopenia. Posttransplantation lymphoproliferative disorder (PTLD) was diagnosed after biopsy of the lesion was facilitated by the transfusion of 40 units of platelets. Epstein-Barr virus (EBV) DNA was not initially detected in the peripheral blood by real-time polymerase chain reaction, and the blood became positive for EBV at a low level only after more than 6 weeks had passed since the initial identification of detectable intracranial lesions. The patient died of cerebral herniation while donor leukocyte infusion was being prepared, and an autopsy confirmed the diagnosis of EBV-associated PTLD restricted to the CNS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12041675     DOI: 10.1007/bf02982135

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Post-transplant Epstein-Barr virus-associated meningoencephalitis and lymphoid interstitial pneumonitis.

Authors:  K Davis; S Hinrichs; J Fidler; T Henry; J Davis; K Baker; B Gordon; T Gross
Journal:  Bone Marrow Transplant       Date:  1999-08       Impact factor: 5.483

2.  Development of a real-time quantitative assay for detection of Epstein-Barr virus.

Authors:  H G Niesters; J van Esser; E Fries; K C Wolthers; J Cornelissen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 3.  Post-transplant EBV induced lymphoproliferative disorders.

Authors:  K G Lucas; K E Pollok; D J Emanuel
Journal:  Leuk Lymphoma       Date:  1997-03

4.  Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.

Authors:  D J Emanuel; K G Lucas; G B Mallory; M K Edwards-Brown; K E Pollok; P D Conrad; K A Robertson; F O Smith
Journal:  Transplantation       Date:  1997-06-15       Impact factor: 4.939

5.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

6.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

Authors:  C M Rooney; C A Smith; C Y Ng; S K Loftin; J W Sixbey; Y Gan; D K Srivastava; L C Bowman; R A Krance; M K Brenner; H E Heslop
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

7.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

Authors:  E B Papadopoulos; M Ladanyi; D Emanuel; S Mackinnon; F Boulad; M H Carabasi; H Castro-Malaspina; B H Childs; A P Gillio; T N Small
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

8.  Donor B cell lymphoma of the brain after allogeneic bone marrow transplantation for acute myeloid leukemia.

Authors:  A Verschuur; N Brousse; B Raynal; O Brison; P Rohrlich; C Rahimy; E Vilmer
Journal:  Bone Marrow Transplant       Date:  1994-09       Impact factor: 5.483

9.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome.

Authors:  M Benkerrou; J P Jais; V Leblond; A Durandy; L Sutton; P Bordigoni; J L Garnier; J Le Bidois; F Le Deist; S Blanche; A Fischer
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

  10 in total
  5 in total

Review 1.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.

Authors:  Frank Lieberman; Victor Yazbeck; Anastasios Raptis; Raymond Felgar; Michael Boyiadzis
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

3.  Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder.

Authors:  Hiroaki Shimizu; Takayuki Saitoh; Hiroko Koya; Akinori Yuzuriha; Takumi Hoshino; Nahoko Hatsumi; Satoru Takada; Tomohito Nagaki; Yoshihisa Nojima; Toru Sakura
Journal:  Int J Hematol       Date:  2011-10-29       Impact factor: 2.490

4.  [How I diagnose and treat post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation].

Authors:  L P Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

5.  Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Diagnosed by Peripheral Facial Nerve Palsy.

Authors:  Aya Imafuku; Kiho Tanaka; Yuji Marui; Yoshifumi Ubara; Kenmei Takaichi; Shinji Tomikawa; Yasunori Ota; Takeshi Fujii; Yasuo Ishii
Journal:  Intern Med       Date:  2018-02-09       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.